Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06916416
PHASE2
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
Sponsor: University of Cologne
View on ClinicalTrials.gov
Summary
By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-06
Completion Date
2028-06
Last Updated
2025-04-08
Healthy Volunteers
No
Conditions
Interventions
DRUG
Pembrolizumab
6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by radiotherapy 20Gy